Home

INmune Bio, Inc. Announces First Quarter 2021 Results and Provides Business Update

Daniel Carlson -
0
TW's Take: INmune continues to make solid progress on all fronts. The rest of 2021 should have some exciting catalysts with Quellor data, Xpro...
Read more

Amryt Reports Record Q1 2021 Financial and Operating Results

Daniel Carlson -
0
TW's Take: nice to see the guidance increased and it's obvious that the core business is going very well at Amryt, but the key...
Read more

Amryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and...

Daniel Carlson -
0
TW's Take: we have been expecting Amryt to make an acquisition and this one is exciting. The prospects for MYCAPSSA are quite strong and...
Read more

Lantern Shines During Biotech Blackout

Daniel Carlson -
0
Biotech stocks continue to take it on the chin. This is the result of an overall shift from growth to value in the market...
Read more

Lantern Pharma Reports First Quarter 2021 Financial Results and Operational Highlights

Daniel Carlson -
0
DALLAS, May 3, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform...
Read more

Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern’s Artificial Intelligence...

Daniel Carlson -
0
TW's Take: this is very exciting news for Lantern as it is the first time they have licensed their RADR platform for third party...
Read more

Alpha-Bet Soup

Daniel Carlson -
4
There are times when stock picking isn't the most important part of your investment strategy. When all that matters is being in the right...
Read more

Trading Blog, April 30, 2021

Daniel Carlson -
0
~ Trade alerts discuss changes to Tailwinds' managed portfolios. They are available for premium subscribers only. The information contained here is not meant to...
Read more

Trade Alert, April 29th, 2021

Daniel Carlson -
1
~ Trade alerts discuss changes to Tailwinds' managed portfolios. They are available for premium subscribers only. The information contained here is not meant to...
Read more

QUEST® PROGANICS™ PROVIDES A TRANSFORMATIVE STEP FORWARD IN ORGANICS RECYCLING

Daniel Carlson -
0
TW's Take: we continue to believe that Quest represents a differentiated offering in the traditional business of waste disposal. In a world increasingly focused...
Read more

Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 4.6 Billion...

Daniel Carlson -
0
TW's Take: the rapid growth of datapoints on their A.I. platform is cementing Lantern (LTRN) as a leader in this field. A.I. is changing...
Read more

Trading Blog, April 27th

Daniel Carlson -
0
~ Trade alerts discuss changes to Tailwinds' managed portfolios. They are available for premium subscribers only. The information contained here is not meant to...
Read more

Sequans Communications Announces First Quarter 2021 Financial Results

Daniel Carlson -
0
TW's Take: very disappointing number and guidance, which points towards management mistakes. SQNS is very well positioned for 5G and IoT, which is looking...
Read more

Lantern Pharma Announces Publication Detailing Preclinical Results of Drug Candidate, LP-184, in a Spectrum...

Daniel Carlson -
0
TW's Take: our take is that LP-184 has the potential to be a billion dollar or more asset as it has shown potential potency...
Read more

The Lows Appear To Be In Place

Daniel Carlson -
9
Earlier this year I was preaching caution. The markets were en fuego and, simply put, this cannot last. While I run pretty fully invested...
Read more

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data...

Daniel Carlson -
0
TW's Take: more overwhelmingly positive data from the VenoValve presented at the leading global vascular symposium. We continue to think the product will be...
Read more

XPro1595: A Next-Generation TNF Inhibitor

Daniel Carlson -
4
We had the opportunity to meet virtually with INmune Bio (INMB) recently. In that meeting, with their CFO, David Moss, and Director of Neuroscience,...
Read more

Anixa Biosciences and Moffitt Cancer Center Report US FDA Request of Additional Information for...

Daniel Carlson -
0
TW's Take: Obviously not a positive, but I'm not concerned about this making it into the clinic eventually. It's a high-risk/high-reward program. The vast...
Read more

How Long Can You Hold A Soccer Ball Under Water?

Daniel Carlson -
6
Last week I wrote about INmune Bio (INMB). In that piece, In Defense of INmune, I discussed the increasing spread between perception of what's...
Read more

Atomera Appoints Sudarsan Srinivasan as Vice President of Engineering

Daniel Carlson -
1
TW's Take: "Atomera's MST technology enables further transistor dimensional scaling for faster computation without compromising power efficiency in leading and mature nodes." Bringing in...
Read more

Become a TW Research Member

All our articles are free for everyone to enjoy, however you must register as a user. Please take the time to sign up, it’s free and we do not share your information with anyone.

For those interested in receiving alerts when we buy or sell stocks for our managed accounts, you should consider becoming a premium subscriber. A premium subscription costs $500 per year and subscribers get emails about every transaction taken in our portfolios, including names that have yet to be added to the Tailwinds site.

SIGN ME UP

Receive Our Weekly Newsletter

Every Sunday we recap the market and consolidate the news from our universe. It’s free to subscribe. Just click on the link below.

Newsletter Signup

© TW Research Group LLC
DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.